GTAB B — Glycorex Transplantation AB (publ) Income Statement
0.000.00%
Last trade - 00:00- SEK147.71m
- SEK147.94m
- SEK35.16m
Annual income statement for Glycorex Transplantation AB (publ), fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | IFRS | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 27 | 28.2 | 36.1 | 30 | 35.2 |
| Cost of Revenue | |||||
| Gross Profit | 24.6 | 24.9 | 31.5 | 26.9 | 28.2 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 34.7 | 40 | 44.4 | 60.2 | 45.6 |
| Operating Profit | -7.72 | -11.8 | -8.31 | -30.3 | -10.4 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -8.05 | -12.2 | -8.52 | -30.4 | -11 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -8.04 | -12.2 | -8.58 | -30.4 | -10.9 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -8.04 | -12.2 | -8.58 | -30.4 | -10.9 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -8.04 | -12.2 | -8.58 | -30.4 | -10.9 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.103 | -0.166 | -0.116 | -0.243 | -0.148 |
| Dividends per Share |